India emerging as global diabetes research hub
By: IPP Bureau
Last updated : November 21, 2026 10:30 am
From GLP-1-producing engineered bacteria and gut microbiome research to genetic therapies and precision medicine: Minister Jitendra Singh
India is stepping up its ambition to become a global powerhouse in diabetes research, with more than a dozen projects underway to develop next-generation therapies, genetic interventions and innovative approaches to disease prevention, according to Union Minister Jitendra Singh.
The research initiatives, being undertaken largely through the Department of Biotechnology (DBT), with some involving the Council of Scientific and Industrial Research (CSIR), reflect India's growing shift towards molecular medicine, precision healthcare and indigenous treatment solutions.
Addressing the inaugural ceremony of RSSDI 2026 in Bengaluru, Singh said India's enormous population and genetic diversity provide a unique scientific advantage, offering opportunities to develop healthcare solutions that could benefit not just the country but the world.
He, however, delivered a pointed message on the growing threat of lifestyle-related diseases, warning that preventing obesity and diabetes among young Indians must be treated as a national responsibility rather than a challenge confined to doctors and healthcare professionals.
"Preventing obesity and diabetes among India’s youth is a national responsibility, not merely a medical challenge," he said, calling for a collective response involving scientists, policymakers, medical professionals and society.
The November 19–22 conference has brought together leading diabetologists, clinicians, researchers, academicians and healthcare professionals from India and abroad. Among those present at the inaugural ceremony were Karnataka Minister for Greater Bengaluru Development and Parliamentary Affairs Krishna Byre Gowda and Member of Parliament C. N. Manjunath.
From imported solutions to indigenous scientific innovation
Highlighting India's expanding research capabilities, Singh said the country has moved decisively from dependence on external healthcare solutions to developing its own vaccines, antibiotics, therapies and advanced medical technologies.
Citing India's DNA-based COVID-19 vaccine, indigenous antibiotics, biosimilars, genetic therapy research and the India Genome Study, he said the country's scientific ecosystem is increasingly equipped to tackle complex healthcare challenges.
He also pointed to advances in vaccine development targeting HPV, dengue and malaria, alongside emerging work in genetic therapies, as evidence of India's growing contribution to global biomedical research.
The next frontier, he said, lies in precision medicine and molecular-level interventions that can help scientists understand, prevent and treat Type 2 diabetes and associated metabolic disorders, particularly among younger populations.
Singh called for stronger partnerships between government research institutions, private-sector researchers, clinicians, startups and medical associations, stressing that scientific discoveries must translate into affordable and accessible healthcare solutions.
Engineered bacteria, gut microbiome and GLP-1 research take centre stage
Among the most promising initiatives is an Indo-Danish collaborative study investigating India-specific changes in gut microbiota among prediabetic and diabetic patients. The research aims to deepen understanding of how gut microbial patterns influence metabolic disorders.
Another DBT-supported project is exploring genetically engineered E. coli Nissle 1917 capable of producing GLP-1, a hormone associated with blood glucose regulation. The approach could potentially pave the way for probiotic-based delivery of therapeutic molecules through the gastrointestinal tract, with human studies expected to be undertaken.
Research at BRIC-THSTI is also examining the expression of GLP-1 analogues in gut-associated bacteria, opening another potential avenue for developing innovative GLP-1-based therapies.
Together, these projects underline the growing emphasis on developing new biological and molecular approaches to diabetes management.
Research targets diabetes risk from pregnancy to childhood
The Minister also highlighted research examining how metabolic risks can be reduced much earlier in life, including interventions beginning before conception and extending into early childhood.
These studies are investigating childhood blood glucose, blood pressure and adiposity, while the EINSTEIN study in rural Mysuru is expected to generate valuable evidence for strengthening preventive healthcare strategies.
Other research is examining how maternal nutrition during pregnancy can influence the metabolic health of offspring, highlighting the importance of addressing diabetes risk across generations.
New biomarkers and molecular targets offer fresh possibilities
Singh outlined several other research initiatives exploring the biological mechanisms behind diabetes and its complications.
These include research combining exosomal profiling and metabolomics to identify biomarkers that could help predict Type 2 diabetes among women with a history of gestational diabetes.
Scientists are also investigating the relationship between Type 2 diabetes and metabolic dysfunction-associated fatty liver disease (MAFLD), including the role of the S100A6 pathway and the development of a potential neutralising monoclonal antibody.
Other projects are examining hyperinsulinemia, hepatic SIRT1 and systemic insulin resistance, alongside the role of ribosomal proteins in insulin signalling.
Research into arachidonic acid is also exploring its potential to improve glucose regulation while protecting skeletal muscles against diabetes-associated wasting.
Another emerging area is macrophage Gi signalling, being investigated as a potential therapeutic target for obesity and Type 2 diabetes. Singh referred to findings published in the Journal of Clinical Investigation in September 2026.
Temperature-resilient insulin, oral insulin and affordable treatments
India is also exploring solutions to practical barriers in diabetes care, including insulin storage and transportation.
Singh referred to ongoing efforts to develop temperature-resilient insulin, which could help address challenges associated with maintaining storage conditions, particularly in difficult settings.
Startups are also investigating oral insulin, potentially opening new possibilities for diabetes treatment and delivery.
Pointing to indigenous biosimilar development, including liraglutide and insulin Lispro, he said India is strengthening its capacity to develop more affordable treatment options.
He emphasised the importance of institutional support, technological innovation and the willingness to take calculated risks in advancing next-generation healthcare solutions.
India's genetic diversity: A major advantage for precision medicine
Singh said India's population diversity and expanding genomic research infrastructure could give the country a significant edge in precision medicine.
Referring to the India Genome Study, which involved 10,000 individuals across 84 population groups, he said the country's genetic diversity represents an invaluable scientific resource for understanding disease patterns and developing more targeted healthcare interventions.
He said these capabilities could help India generate research with global relevance while strengthening its own response to complex metabolic and genetic disorders.
Minister warns against health misinformation and unprescribed weight-loss drugs
Beyond research and technology, Singh raised concerns about the growing spread of misinformation surrounding diabetes, obesity, nutrition and weight-loss treatments.
He urged the medical and scientific community to actively counter misleading dietary advice circulated by self-styled nutritionists, unscientific health claims and the unprescribed use of weight-loss drugs.
Warning that misinformation can be more damaging than a lack of information, he called on credible scientific voices to engage more actively with the public and ensure that health decisions are based on evidence and responsible medical guidance.
Protecting India's young population is a national priority
Linking the diabetes challenge to India's long-term development ambitions, Singh said protecting the health and productive potential of the country's young population was essential to achieving Viksit Bharat by 2047.
With nearly 70 per cent of India's population below the age of 40, he said the country cannot afford to ignore the growing risks of obesity and diabetes among its younger generations.
The fight against these conditions, he stressed, must extend beyond hospitals and clinics to schools, communities, scientific institutions and policymaking platforms.
Calling on RSSDI and the wider medical research community to strengthen collaboration with India's scientific institutions, Dr. Singh urged researchers to accelerate the development of preventive, affordable and next-generation healthcare solutions.
The message from the conference was clear: India's diabetes challenge demands more than treatment. It calls for scientific innovation, early prevention, indigenous research and a concerted national effort to protect the health of future generations.